Literature DB >> 17072500

Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers.

I Zidi1, C Guillard, C Marcou, I Krawice-Radanne, D Sangrouber, N Rouas-Freiss, E D Carosella, P Moreau.   

Abstract

HLA-G is expressed by tumors, in which it contributes to the evasion of immunosurveillance. NF-kappaB appears to be a candidate for regulating HLA-G expression, since it is considered to be a hallmark of cancer. We investigated the role of NF-kappaB in modulating HLA-G expression in HLA-G-positive tumor cells, JEG-3 (choriocarcinoma), FON (melanoma), and M8-HLA-G1 (HLAG1-transfected melanoma). The treatment of tumor cells with two NF-kappaB inducers, tumor necrosis factor-alpha and phorbol 12-myristate 13-acetate, decreased HLA-G1 cell surface expression but increased intracytoplasmic HLA-G proteins. Reduction in HLA-G1 cell surface expression is driven by NF-kappaB and involves a proteolytic shedding process dependent on metalloproteinase activity. In contrast, an increase in intracytoplasmic HLA-G proteins involves post-transcriptional mechanisms that are independent of NF-kappaB. These results, and the fact that soluble HLA-G1 reduces the cytotoxicity of the NKL cell line, lead us to propose a novel regulatory pathway for HLA-G expression by tumor cells that may have particular relevance in tumor escape.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072500     DOI: 10.1007/s00018-006-6341-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  19 in total

Review 1.  HLA-G regulators in cancer medicine: an outline of key requirements.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Tumour Biol       Date:  2011-07-27

2.  Soluble HLA-G induces NF-kappaB activation in natural killer cells.

Authors:  I Zidi; C Guillard; E D Carosella; P Moreau
Journal:  J Physiol Biochem       Date:  2010-04-20       Impact factor: 4.158

Review 3.  Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?

Authors:  Laurence Amiot; Soldano Ferrone; Hans Grosse-Wilde; Barbara Seliger
Journal:  Cell Mol Life Sci       Date:  2010-11-10       Impact factor: 9.261

Review 4.  TNF-alpha and its inhibitors in cancer.

Authors:  Inès Zidi; Souhir Mestiri; Aghleb Bartegi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

5.  Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu.

Authors:  Angel Díaz-Lagares; Estibaliz Alegre; Joel LeMaoult; Edgardo D Carosella; Alvaro González
Journal:  Immunology       Date:  2008-09-01       Impact factor: 7.397

Review 6.  Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance.

Authors:  Anita Q Gomes; Daniel V Correia; Bruno Silva-Santos
Journal:  EMBO Rep       Date:  2007-11       Impact factor: 8.807

7.  Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding.

Authors:  Roberta Rizzo; Alessandro Trentini; Daria Bortolotti; Maria C Manfrinato; Antonella Rotola; Massimiliano Castellazzi; Loredana Melchiorri; Dario Di Luca; Franco Dallocchio; Enrico Fainardi; Tiziana Bellini
Journal:  Mol Cell Biochem       Date:  2013-06-05       Impact factor: 3.396

Review 8.  The role of HLA-G in immunity and hematopoiesis.

Authors:  Edgardo D Carosella; Silvia Gregori; Nathalie Rouas-Freiss; Joel LeMaoult; Catherine Menier; Benoit Favier
Journal:  Cell Mol Life Sci       Date:  2010-11-30       Impact factor: 9.261

Review 9.  Non-classical transcriptional regulation of HLA-G: an update.

Authors:  Philippe Moreau; Sébastien Flajollet; Edgardo D Carosella
Journal:  J Cell Mol Med       Date:  2009-06-05       Impact factor: 5.310

10.  HLA-G dimers in the prolongation of kidney allograft survival.

Authors:  Maureen Ezeakile; Vera Portik-Dobos; Juan Wu; Daniel D Horuzsko; Rajan Kapoor; Muralidharan Jagadeesan; Laura L Mulloy; Anatolij Horuzsko
Journal:  J Immunol Res       Date:  2014-03-30       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.